Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-26T13:12:01.746Z Has data issue: false hasContentIssue false

Chapter 21 - Pharmacogenomics to Link Genetic Background with Therapeutic Efficacy and Safety

from Section five - Chemical Genomics and Medicine

Published online by Cambridge University Press:  05 June 2012

By
Mark M. Bouzyk ,
Weining Tang  and
Brian Leyland-Jones
Edited by
Haian Fu
Haian Fu
Affiliation:
Emory University, Atlanta
Get access

Summary

Pharmacogenomics (PGx) is a rapidly evolving science with the potential to transform the way in which medicines are developed and prescribed. It represents a new era in patient treatment and will enable delivery of medicines in a safer and more efficacious manner. The aim of PGx is to optimize drug therapy with respect to the individual's genetic profile by associating genetic markers (e.g., single-nucleotide polymorphisms [SNPs] or gene expression) with the drug's safety or efficacy, thereby heralding the advent of personalized medicine (the right drug for the right person), whereby a drug may be selected or optimized for a specific individual based on his or her genetic characteristics. Recent advances, approaches, technologies, and resources in this field are highlighted in this chapter and interlaced with established and new exemplars.

Definition

Often, the term pharmacogenomics is used interchangeably with pharmacogenetics, and it has proved difficult to define each concisely. However, it is generally accepted that pharmacogenomics takes into account the whole genome in a wide application of genomic technologies used to predict drug efficacy and safety in order to characterize current drugs or discover new drugs while considering genetic variation, whereas PGx is seen as the study of inherited genetic variation that may be associated with different response or adverse events to drugs by assessing typically one or a few candidate genes.

Type
Chapter
Information
Chemical Genomics , pp. 293 - 300
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lazarou, JPomeranz, B. HCorey, P.N 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA 279 1200Google Scholar
Ingelman-Sundberg, MRodriguez-Antona, C 2005 Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapyPhilos Trans R Soc Lond B Biol Sci 360 1563Google Scholar
Phillips, K. AVeenstra, D. LOren, ELee, J. KSadee, W 2001 Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic reviewJAMA 286 2270Google Scholar
Mancinelli, LCronin, MSadee, W 2000 Pharmacogenomics: the promise of personalized medicineAAPS PharmSci 2Google Scholar
Garrod, A. E 1902 The incidence of alcaptonuria: a study in chemical individualityLancet ii 1616Google Scholar
Garrod, A. E 1909 Inborn Errors of MetabolismNew YorkOxford University Press
Brown, S. M 2003 Essentials of Medical GenomicsNew YorkWiley-Liss
Forbat, ALehmann, HSilk, E 1953 Prolonged apnoea following injection of succinyldicholineLancet 265 1067Google Scholar
La Du, B. NBartels, C. FNogueira, C. PHajra, ALightstone, HVan der Spek, ALockridge, O 1990 Phenotypic and molecular biological analysis of human butyrylcholinesterase variantsClin Biochem 23 423Google Scholar
Bonicke, RLisboa, B. P 1956 Uber die erbbedingtheit der intraindividuellen konstanz der isoniaszidausscheidung beim menschem (untersuchungen an eineiigen und zweieiigen zwiuingenNaturwissenschaften 44Google Scholar
Motulsky, A. G 1957 Drug reactions enzymes, and biochemical geneticsJ Am Med Assoc 165 835Google Scholar
Mahgoub, AIdle, J. RDring, L. GLancaster, RSmith, R. L 1977 Polymorphic hydroxylation of Debrisoquine in manLancet 2 584Google Scholar
Gonzalez, F. JSkoda, R. CKimura, SUmeno, MZanger, U. MNebert, D. WGelboin, H. VHardwick, J. PMeyer, U. A 1988 Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature 331 442Google Scholar
Veenstra, D. L 2004 The interface between epidemiology and pharmacogenomicsHuman Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent DiseaseKhoury, M. KLittle, JBurke, WNew YorkOxford University Press
Gough, A. CMiles, J. SSpurr, N. KMoss, J. EGaedigk, AEichelbaum, MWolf, C. R 1990 Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature 347 773Google Scholar
Shargel, LWu-Pong, SYu, A 2005 Applied Biopharmaceuticals & PharmacokineticsNew YorkMcGraw-Hill
Allison, M 2008 Is personalized medicine finally arriving?Nat Biotechnol 26 509Google Scholar
Weinshilboum, R 2003 Inheritance and drug responseN Engl J Med 348 529Google Scholar
Evans, W. EMcLeod, H. L 2003 Pharmacogenomics–drug disposition, drug targets, and side effectsN Engl J Med 348 538Google Scholar
Baselga, J 2006 Targeting tyrosine kinases in cancer: the second waveScience 312 1175Google Scholar
Duffy, M. J 2005 Predictive markers in breast and other cancers: a reviewClin Chem 51 494Google Scholar
Sjoblom, TJones, SWood, L. DParsons, D. WLin, JBarber, T. DMandelker, DLeary, R. JPtak, JSilliman, NSzabo, SBuckhaults, PFarrell, CMeeh, PMarkowitz, S. DWillis, JDawson, DWillson, J. KGazdar, A. FHartigan, JWu, LLiu, CParmigiani, GPark, B. HBachman, K. EPapadopoulos, NVogelstein, BKinzler, K. WVelculescu, V. E 2006 The consensus coding sequences of human breast and colorectal cancersScience 314 268Google Scholar
Spear, B. BHeath-Chiozzi, MHuff, J 2001 Clinical application of pharmacogeneticsTrends Mol Med 7 201Google Scholar
Austin, MBabbiss, L 2006 Commentary: when and how biomarkers could be used in 2016AAPS J 8 E185Google Scholar
Ansell, JHirsh, JPoller, LBussey, HJacobson, AHylek, E 2004 The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest 126 204SGoogle Scholar
Higashi, M. KVeenstra, D. LKondo, L. MWittkowsky, A. KSrinouanprachanh, S. LFarin, F. MRettie, A. E 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA 287 1690Google Scholar
Rieder, M. JReiner, A. PGage, B. FNickerson, D. AEby, C. SMcLeod, H. LBlough, D. KThummel, K. EVeenstra, D. LRettie, A. E 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin doseN Engl J Med 352 2285Google Scholar
Matthews, A 2007
Mallal, SPhillips, ECarosi, GMolina, J. MWorkman, CTomazic, JJagel-Guedes, ERugina, SKozyrev, OCid, J. FHay, PNolan, DHughes, SHughes, ARyan, SFitch, NThorborn, DBenbow, A 2008 HLA-B*5701 screening for hypersensitivity to abacavirN Engl J Med 358 568Google Scholar
Hughes, A. RSpreen, W. RMosteller, MWarren, L. LLai, E. HBrothers, C. HCox, CNelsen, A. JHughes, SThorborn, D. EStancil, BHetherington, S. VBurns, D. KRoses, A. D 2008 Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utilityPharmacogenomics J 8 365Google Scholar
Gunderson, K. LSteemers, F. JLee, GMendoza, L. GChee, M. S 2005 A genome-wide scalable SNP genotyping assay using microarray technologyNat Genet 37 549Google Scholar
Hardiman, G 2004 Microarray platforms – comparisons and contrastsPharmacogenomics 5 487Google Scholar
Wick, IHardiman, G 2005 Biochip platforms as functional genomics tools for drug discoveryCurr Opin Drug Discov Devel 8 347Google Scholar
Li, MLi, CGuan, W 2008 Evaluation of coverage variation of SNP chips for genome-wide association studiesEur J Hum Genet 16 635Google Scholar
Michalets, E. L 1998 Update: clinically significant cytochrome P-450 drug interactionsPharmacotherapy 18 84Google Scholar
Klein, T. EChang, J. TCho, M. KEaston, K. LFergerson, RHewett, MLin, ZLiu, YLiu, SOliver, D. ERubin, D. LShafa, FStuart, J. MAltman, R. B 2001 Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge BasePharmacogenomics J 1 167Google Scholar
Sangkuhl, KBerlin, D. SAltman, R. BKlein, T. E 2008 PharmGKB: understanding the effects of individual genetic variantsDrug Metab Rev 40 539Google Scholar
Hernandez-Boussard, TWhirl-Carrillo, MHebert, J. MGong, LOwen, RGong, MGor, WLiu, FTruong, CWhaley, RWoon, MZhou, TAltman, R. BKlein, T. E 2008 The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledgeNucleic Acids Res 36 D913Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×